Glenmark to Pay $29.6M Over Generic Drug Price Fixing Claims

Drug manufacturer Glenmark has agreed to pay $29.6 million to settle a major lawsuit. A coalition of 48 states and territories accused the company of taking part in a scheme to keep generic medication prices artificially high. The legal action centered on activities between May 2009 and December 2019.

Regulators claimed that Glenmark worked with other companies to limit competition through secret meetings and private communications. These actions allegedly forced customers to pay more than they should have for their prescriptions over a ten year period. The settlement is intended to provide restitution to those affected by these antitrust violations.

If you purchased qualifying generic drugs during that time frame, you may be eligible for a payment. The process for filing a claim is expected to open soon on an official state website. The settlement funds will be distributed across the country with states like California, Texas, and New York receiving the largest shares.

While this case does not directly involve digital assets, it serves as a reminder of how federal and state regulators monitor market manipulation. Traders often watch how government agencies handle large antitrust cases to understand how they might approach future enforcement actions in the crypto sector.